RecruitingNot ApplicableNCT06181929

A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females

A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females Who Are Never Smoker with a Family History of Lung Cancer


Sponsor

Sang-Won Um

Enrollment

200 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a single-arm prospective pilot study in a single institution. The target accrual is 200 participants of Korean, female sex, never smoker status, and family history of lung cancer. The study will aim to enroll 200 participants in two years.


Eligibility

Sex: FEMALEMin Age: 45 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for early-stage lung cancer in Korean women who have never smoked but have a family history of lung cancer. Non-smoking women with a family history of lung cancer are a high-risk group that is often missed by standard screening programs designed for heavy smokers. **You may be eligible if...** - You are a Korean woman between 45 and 74 years old - You have never smoked (fewer than 100 cigarettes in your lifetime) - You have a first-degree relative (parent, sibling, or child) who has been diagnosed with lung cancer **You may NOT be eligible if...** - You have a prior history of lung cancer - You have been diagnosed with any other cancer within the past 5 years - You are currently participating in another cancer prevention study - You currently have symptoms that suggest possible lung cancer (e.g., unexplained cough, weight loss) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTLow dose CT

A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent


Locations(1)

Samsung Medical Center

Seoul, Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06181929


Related Trials